Is Glaxosmi. Pharma overvalued or undervalued?

As of 16 November 2023, Glaxosmi. Pharma's valuation grade has moved from expensive to very expensive, indicating a significant increase in perceived valuation. The company is currently considered overvalued. Key ratios include a PE ratio of 62.68, an EV to EBITDA ratio of 47.07, and a Price to Book Value of 29.69, all of which are substantially higher than industry norms.
In comparison to its peers, Glaxosmi. Pharma's PE ratio is notably higher than Sun Pharma's 35.25 and Cipla's 22.99, which are categorized as expensive and attractive, respectively. Additionally, the company's ROE stands at a remarkable 47.36%, yet this is overshadowed by its very high valuation metrics. Despite outperforming the Sensex with a year-to-date return of 53.11% compared to the Sensex's 5.63%, the elevated valuation ratios suggest that the stock may not be a prudent investment at this time.